Navigation Links
Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant

LAWRENCE, Mass., May 14, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One™ patient Nikolas Gieske of Mequon, Wisconsin, received a kidney transplant following four successful years of more frequent home hemodialysis with the System One.

(Logo: )

The freedom to do his dialysis treatments on his own schedule enabled Nikolas to live more independently while pursuing his college degree at the Milwaukee School of Engineering, where he is currently enrolled in his junior year and studying software engineering. In September of 2011, Nikolas, who was on a transplant list, learned there was a "perfect-match" kidney available for him, and underwent the transplant procedure shortly after. 

"I only wanted to pursue a kidney transplant if it was a perfect match for me because I already had a high quality of life as a System One patient," says Nikolas Gieske. "I believe my more frequent therapy schedule played a role in helping me to be healthy enough to receive my new kidney. The ability of the System One to take a complex medical treatment, and engineer it to be easy to use has inspired me to pursue a career in engineering. I hope to someday be able to design similar products to help people."

In addition to his parents, Nikolas' brother, Mitchell, helped Nikolas receive treatments with the System One as one of his trained partners. Through his experience as a dialysis care partner, Mitchell was inspired to pursue a career in medicine, and was recently accepted on a full academic scholarship to the Milwaukee School of Engineering School of Nursing. Mitchell will join his brother as a student in Fall 2013.

"NxStage is excited to celebrate Nikolas' successful transplant," says Jeffrey Burbank, Chief Executive Officer of NxStage Medical. "Given the growing clinical evidence in support of more frequent, daily home hemodialysis, it's clear that our therapy allows many of our patients to live longer, better lives."

To learn more about Nikolas' story visit:

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
6. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
9. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
10. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
11. SCAI Statement on the Hospitalization of Former President Bill Clinton
Post Your Comments:
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):